مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

ATEZOlizumab / BEVAcizumab

ATZBEV-OO-O3-CN-ML

Ministry of Health

Name:	**File #:**	**Ht (cm):**
Nationality:	**Civil ID:**	**Wt (Kg):**
Gender/Age:	**DOB:**	**BSA (m²):**

Indication(s): ☐ Advanced stage NSCLC (IMPower 150).
☐ Unresectable hepatocellular carcinoma with no prior systemic therapy (IMbrave150 Trial).

Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Parameters: Urine dipstick ≤ +2 (If Urine dipstick > 2, Do urine protein/creatine ratio And give bevacizumab If the ratio < 2).
BP ≤ 150/90 mmHg.

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
ATEZOlizumab (Tecentriq®)	1200 mg	IV in 250 mL NS over 60 min. If the initial infusion is well tolerated, shorten the subsequent infusions to 30 min.	D1
BEVAcizumab (Avastin®)	15 mg/kg	IV in 100 mL NS over 90 min. If the initial infusion is well tolerated, shorten second infusion to 60 min. If the second infusion is well tolerated, shorten the subsequent infusions to 30 min.	D1
To be repeated every 3 weeks till disease progression or intolerable toxicities.			

Treatment Description:

Cycle	Date	Tecentriq®	Avastin®	Bl. Pr.	Wt (Kg)	Physician	Consultant
C# __							
C# __							
C# __							
C# __							
C# __							
C# __							

Important Notes:

Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological

If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No